Articles

Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer

Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo
Oncology Unit, IRCCS Humanitas Institute, Rozzano
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo
Oncology Unit, IRCCS National Cancer Institute, Milan
Oncology Unit, Hospital San Filippo Neri, Rome
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo
Department of Management, Information and Production Engineering, University of Bergamo, Bergamo
Department of Management, Information and Production Engineering, University of Bergamo, Bergamo
Oncology Unit, Hospital Papa Giovanni XXIII, Bergamo
Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio
Oncology Unit, IRCCS Cancer Institute Giovanni Paolo II, Bari
Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio
Medical Oncology and Internal Medicine, Policlinico San Marco, Zingonia-Bergamo
Oncology Unit, Hospital San Filippo Neri, Rome
Oncology Unit, IRCCS National Cancer Institute, Milan
Oncology Unit, IRCCS Humanitas Institute, Rozzano
Department Oncology Bergamo Province, Hospital Papa Giovanni XXIII, Bergamo
Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo;University of Milan Bicocca, School of Medicine and Surgery, Milan, Italy
Vol. 105 No. 6 (2020): June, 2020 https://doi.org/10.3324/haematol.2019.228981